Document:

Exhibit 10.54

 

RELEASE AND SETTLEMENT

 

Dated
this 1st day of March 2011, by and between Viral Genetics, Inc., a Delaware corporation ("Viral") and DMBM,
Inc., a New York corporation ("DMBM").

 

WHEREAS DMBM has agreed to purchase a 5% Unsecured Convertible
Debenture issued December 3, 2009 in the principal amount of $132,000 (the "Note") from the University of Vermont State
and Agricultural College under an Assignment Agreement dated March 1, 2011 (the "Assignment"); and

 

WHEREAS payment of the Purchase Price (as defined in the Assignment)
for the Note is in Payment Tranches (as defined in the Assignment), and DMBM and Viral are mutually desirous of irrevocably establishing
the terms of settling and releasing the Note in advance but which shall take effect upon completion of each Payment Tranche,

 

NOW THEREFORE for good and lawful consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties agree as follows.

 

	1.		Upon payment of each Payment Tranche, DMBM hereby:

	a.		represents and warrants that it will have full right, title and ownership to the Note
Tranche described in the Assignment under Section 2;

	b.		irrevocably tenders and assigns to Viral full right, ownership and title to the each
Note Tranche in exchange for shares of common stock of Viral at the price of $0.01 per share for an aggregate of fourteen million,
two hundred and seventy eight thousand, one hundred (14,278,100) shares of common stock. of Viral for the entire Note, including
shares issuable for accrued interest; and

	c.		provides a complete and irrevocable release of any and all liabilities, fees, penalties,
interests or claims of any kind in regard to each Note Tranche so purchased and the amounts owed pursuant thereto, and acknowledges
that, upon tender of the final Note Tranche, the Note in its entirety shall be and is satisfied in full.

	2.		This agreement shall be governed by the laws of the State of California.

	3.		If any of the Payment Tranches is not completed on the timeline specified in the Assignment
Agreement, only those Note Tranches that have been so paid for shall be tendered, released and settled hereunder and otherwise
this Agreement shall terminate.

 

 

Agreed as of the date affixed hereof.Exhibit 10.55

 

NOTE PURCHASE AGREEMENT

 

THIS AGREEMENT is made this 10th day of March, 2011 by
and among the University License Equity Holdings, Inc., a Colorado non-profit corporation (“Assignor”), DMBM Inc.,
a New York Corporation (“Assignee”) and Viral Genetics, Inc., a Delaware corporation (the “Company”)

 

WHEREAS, Assignor holds a 5% Unsecured Convertible Debenture in
the original principal amount of $116,108.19 (the “Note”), having an outstanding balance as of the date of this Agreement
of $123,765.60 (principal plus accrued interest);

 

WHEREAS, Assignor is desirous of selling the Note in six tranches
(the “Tranches”) to Assignee on the terms and subject to the conditions set forth in this Agreement, and Assignee is
desirous of same;

 

NOW, THEREFORE, for good and valuable consideration, the receipt
and legal sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

1.     Purchase and Sale of Note Interests.
Assignor hereby agrees to sell, assign and transfer to Assignee all of Assignor’s right, title and interest in and to the
Note, and Assignee hereby agrees to purchase the Note for a purchase price equal to the current balance of the Note plus accrued
interest through the date on which the Purchase Price is paid in full. Upon payment by Assignee to Assignor of the entire principal
balance of the Note, together with accrued interest (the “Purchase Price”. Assignee shall be the holder of the Note
for all purposes. Prior to payment in full of the Purchase Price, Assignor shall remain the sole holder of the Note.

 

2.       Payment of Purchase
Price. The Purchase Price shall be paid in six Tranches as follows: Upon each such payment, (a) Assignee shall become the owner
of all rights arising under the Note with respect to the purchased Tranche, including conversion rights set forth in the Note,
and (b) Assignor relinquishes all rights and recourse against the Company in the amount of the purchased Tranche.

 

$20,000 on or before April 20, 2011;

$20,000 on or before May 7, 2011;

$20,000 on or before June 4, 2011;

$20,000 on or before July 2, 2011;

$20,000 on or before August 30 2011; and

$23,765.60 plus all interest accrued on the Note or before September
27, 2011.

 

3.          Transfer
and Exercise of Conversion Rights. The parties agree that, upon Assignee’s payment of each Tranche amount as set forth
herein, Assignee shall be vested with the right to immediately convert a portion of the indebtedness evidenced by the Note, equal
to the amount paid pursuant to Section 2 above, into Common Stock of the Company equal to the dollar amount purchased divided by
the Conversion Price, which the parties hereby agree shall by $0.01 per share. Upon payment each such Tranche amount, Assignee
and Assignor shall send joint written notice to the Company of the amount paid. Assignee shall then be entitled to provide the
Company with a Notice of Conversion, in the form of Annex I to the Note, effecting the conversion of such Tranche to Common Stock
of the Company. The Company agrees that, notwithstanding that Assignee is not the Holder of record of the Note, the Company will
honor all such Notices of Conversion delivered by Assignee, and will issue Common Stock of the Company to Assignee, in accordance
with this provision, The parties agree that issuance of such shares by the Company shall constitute full satisfaction by the Company
of its obligations under the Note with respect to the converted indebtedness.

    	1

    	 

    

 

4.          Representations
and Warranties of Assignor. Assignor hereby represents, warrants, and covenants to Assignee that Assignor is the sole owner
of and has the exclusive right to the Note, free and clear of any and all liens, encumbrances, licenses, or claims of any nature,
and has made no agreement with respect to same that is in conflict with this Agreement.

 

5.          Representations
and Warranties of Assignee. Assignee hereby represents and warrants to Assignor and the Company as follows:

 

 a. Assignee has full power and authority to enter into this Agreement, and this Agreement, when executed and delivered, will constitute a valid and legally binding obligation of Assignee, enforceable against Assignee in accordance with its terms.

 

 b. Assignee is purchasing the Note, and the Common Stock issuable upon conversion of the Note, for investment purposes and for Assignee’s own account, not as a nominee or again, and not with a view to the resale or distribution of any part thereof, and Assignee has no present intention of selling, granting any participation in, or otherwise distributing the same.

 

 c. Assignee represents that it is an Accredited Investor as defined in Rule 501(a) promulgated under the Securities Act, and that it is experienced in evaluating and investing in securities of companies in a similar stage of development to the Company, and further acknowledges that it can bear the economic risk of such investment, and has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment in the Note.

 

 d. Assignee understands that there is no market for the Note, and that the Note may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Note any and Common Stock issued on conversion of the Note or an available exemption from registration under the Securities Act, the Note and any Common Stock issued on conversion of the Note must be held indefinitely.

 

6.          Forbearance
by Assignor. Assignor agrees that during the terms of this Agreement, unless Assignee defaults in its payment or other obligations
under this Agreement, it will not convert any portion of the Note into stock of the Company.

    	2

    	 

    

 

7.          Default
and Remedies. In the event that Assignee fails to make ant Tranche payment in accordance with the Schedule set forth in Section
2 hereof, Assignor shall have the right to terminate this Agreement by giving written notice to Assignee, and may exercise such
other rights and remedies as may be available under applicable law.

 

8.           General Provisions. This Agreement (a) shall be governed
by and construed under the laws of the State of Colorado, without regard to principles of conflicts of laws; (b) constitutes the
entire agreement between the parties with respect to its subject matter, superceding all prior oral and written communications,
proposals, negotiations, representations, understandings, courses of dealing, agreements, contracts, and the like between or among
any or all of the parties in such respect; (c) may be amended, modified, or terminated only by a writing signed by all parties;
(d) may be executed in facsimile or digital copy, and may exist in counterparts; and (c) shall bind and inure to the benefit of
the parties and their respective successors and assigns, except that no obligation under this Agreement may be delegated, nor
may this Agreement be assigned, without the prior written consent of all parties. Any notice or other communication required or
permitted hereunder shall be in writing, and shall be deemed to have been given when placed in the United States mail, postage
pre-paid, addressed to the last known address of the party to be notified.

 

IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date above first written.

 

	DMBM, Inc.	University License Equity Holdings, Inc.
	A New York corporation	 
	 	 
	By: /s/ Damon R. Devitt	By: /s/ David N. Allen
	Duly Authorized Officer President	Duly Authorized Officer - Secretary
	 	 
	Viral Genetics, Inc.	 
	a Delaware corporation	 
	 	 
	By: /s/ Haig Keledjian	 
	Duly authorized Officer	 

 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]